Şanlı, F. et al. 2020. The AKT antagonist AZD5363 suppresses features associated with cancer progression in human larynx cancer cells. The European Research Journal. 6, 5 (Sep. 2020), 380–387. DOI:https://doi.org/10.18621/eurj.624088.